Correction to: Assessment of Local Adverse Reactions to Subcutaneous Immunoglobulin (SCIG) in Clinical Trials
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1573-2592
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Correction to: Assessment of Local Adverse Reactions to Subcutaneous Immunoglobulin (SCIG) in Clinical Trials ; volume:38 ; number:4 ; day:27 ; month:4 ; year:2018 ; pages:539 ; date:5.2018
Journal of clinical immunology ; 38, Heft 4 (27.4.2018), 539, 5.2018
- Creator
-
Ballow, Mark
- Contributor
-
Wasserman, Richard L.
Jolles, Stephen
Chapel, Helen
Berger, Mel
Misbah, Siraj A.
SpringerLink (Online service)
- DOI
-
10.1007/s10875-018-0504-0
- URN
-
urn:nbn:de:101:1-2018091220470433265888
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:22 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Ballow, Mark
- Wasserman, Richard L.
- Jolles, Stephen
- Chapel, Helen
- Berger, Mel
- Misbah, Siraj A.
- SpringerLink (Online service)
Other Objects (12)
Response to the Letter to the Editor Regarding “Assessment of Local Adverse Reactions to Subcutaneous Immunoglobulin (SCIG) in Clinical Trials”
Adverse reactions to biologics
New Frontiers in Subcutaneous Immunoglobulin Treatment
Neurological adverse reactions to anticancer drugs
Is it safe to switch from intravenous immunoglobulin to subcutaneous immunoglobulin in patients with common variable immunodeficiency and autoimmune thrombocytopenia?
Impact of COVID-19 on adverse reactions to subcutaneous specific immunotherapy in children:a retrospective cohort study
A single centre retrospective study of systemic reactions to subcutaneous immunotherapy
Adverse drug reactions
Implications to payers of switch from hospital-based intravenous immunoglobulin to home-based subcutaneous immunoglobulin therapy in patients with primary and secondary immunodeficiencies in Canada
Overbaked: assessing and predicting acute adverse reactions to Cannabis
Systemic reactions to subcutaneous allergen immunotherapy: real-world cause and effect modelling
Real-World Evidence of Tolerability of 20% Subcutaneous Immunoglobulin Treatment
Response to the Letter to the Editor Regarding “Assessment of Local Adverse Reactions to Subcutaneous Immunoglobulin (SCIG) in Clinical Trials”
Adverse reactions to biologics
New Frontiers in Subcutaneous Immunoglobulin Treatment
Neurological adverse reactions to anticancer drugs
Is it safe to switch from intravenous immunoglobulin to subcutaneous immunoglobulin in patients with common variable immunodeficiency and autoimmune thrombocytopenia?
Impact of COVID-19 on adverse reactions to subcutaneous specific immunotherapy in children:a retrospective cohort study
A single centre retrospective study of systemic reactions to subcutaneous immunotherapy
Adverse drug reactions
Implications to payers of switch from hospital-based intravenous immunoglobulin to home-based subcutaneous immunoglobulin therapy in patients with primary and secondary immunodeficiencies in Canada
Overbaked: assessing and predicting acute adverse reactions to Cannabis
Systemic reactions to subcutaneous allergen immunotherapy: real-world cause and effect modelling
Real-World Evidence of Tolerability of 20% Subcutaneous Immunoglobulin Treatment
Response to the Letter to the Editor Regarding “Assessment of Local Adverse Reactions to Subcutaneous Immunoglobulin (SCIG) in Clinical Trials”
Adverse reactions to biologics
New Frontiers in Subcutaneous Immunoglobulin Treatment
Neurological adverse reactions to anticancer drugs
Is it safe to switch from intravenous immunoglobulin to subcutaneous immunoglobulin in patients with common variable immunodeficiency and autoimmune thrombocytopenia?
Impact of COVID-19 on adverse reactions to subcutaneous specific immunotherapy in children:a retrospective cohort study
A single centre retrospective study of systemic reactions to subcutaneous immunotherapy
Adverse drug reactions
Implications to payers of switch from hospital-based intravenous immunoglobulin to home-based subcutaneous immunoglobulin therapy in patients with primary and secondary immunodeficiencies in Canada
Overbaked: assessing and predicting acute adverse reactions to Cannabis
Systemic reactions to subcutaneous allergen immunotherapy: real-world cause and effect modelling